Abstract 65P
Background
In healthy cells rather than being evenly distributed phosphatidylserine (PS) and phosphatidylethanolamine (PE) are found preferentially in the inner leaflet of the plasma membrane. Unlike normal cells, tumor cells lose the ability to maintain aminophospholipid asymmetry and expose PS naturally which promotes tumor growth and immune suppression by mechanisms that are not established. Since both PS and PE are co-regulated by the same transporters, in the case of PE translocation it might also serve as a specific lipid biomarker diagnostic the prognostic value of which is yet to be determined. We aimed to investigate whether hypoxia and low pH characteristics of tumor microenvironment (TME) might promote PE translocation on the surface leaflet of cancer cells membranes.
Methods
Ovarian cancer cells OVCAR-4 were incubated under standard (pH=7.5, O2=21%) and TME modeling conditions (pH=5.8, О2=1%) following with a two-step staining with PE-specific biotinylated Ro09 and streptavidin conjugated with Alexa Fluor 405. Propidium iodide (PI) staining was conducted to justify plasma membrane integrity. Visualization of PE on living OVCAR-4 cells was performed with the use of laser confocal microscopy.
Results
Under normoxic conditions a signal from PE was not detected on the surface of intact OVCAR-4 cells. However, under TME conditions cells were positive for PE staining, but not for PI, demonstrating that PE is translocated from the inner to the outer leaflet of cancer cell membrane.
Conclusions
Our results show that non apoptotic externalization of aminophospholipids in cancer cells has become a subject of great interest due to correlation with innate immune suppression and promotion of tumor growth. We propose that TME-driven surface exposure of PE, a second abundant phospholipid in cell membrane, coincides with constitutive PS externalization and can serve as a potential TME-specific therapeutic target and/or diagnostic tool for ovarian and other types of cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract